6.79
+2.88%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MicroTech Medical (Hangzhou) Co
Its shares trade on HKEX under the ticker 2235.HK. It has been listed since 19 October 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥769.4m and net income of CN¥46.7m. At that date it held total assets of CN¥2.69bn and shareholders' equity of CN¥2.35bn.
MicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-10-19. The firm's products such as applicator insulin pump system (Equil), blood glucose monitoring system and continuous blood glucose monitoring system (AiDEX G7) have been commercialized. The firm's products, such as artificial pancreas, are in the process of research and development. The firm's products are sold to overseas markets such as the United States and the European Union.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Oct 2021
- Employees
- 659
- Website
- microtechmd.com ↗
Leadership
Pay as last reported
- Dr. Pan ZhengChairman of the Board, Executive Director
- Dr. Yonghui ShiSenior Vice President, Executive Director, Secretary of the Board, Joint Company Secretary, since 2021
- Ms. Xiu LiuExecutive Director
- Dr. Fei YuExecutive Director
- Ms. Pik Man ChuJoint Company Secretary
- Ms. Yun GaoNon-Executive Director
- Mr. Shuo MaoNon-Executive Director
- Dr. Hua ChengNon-Executive Independent Director
- Mr. Kin Cheong HoIndependent Non-Executive Director
- Dr. Lihua LiIndependent Non-Executive Director
- Ms. Chunfeng WangIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MicroTech Medical's Equil insulin pump system is commercialized in global markets.
- The AiDEX G7 continuous glucose monitoring system is a key product for diabetes management.
- 659 full-time employees support research and development in Hangzhou.
Weaknesses
- The company's artificial pancreas is still in R&D phase, not yet commercialized.
- Limited product range compared to competitors in the Health Care sector.
- Dependence on overseas markets like the US and EU for sales.
Opportunities
- Expanding into new markets within the European Union for diabetes management devices.
- Growing demand for continuous glucose monitoring systems in the US market.
- Increasing adoption of diabetes management devices in emerging markets.
Threats
- Regulatory challenges in the US and EU for medical device approvals.
- Competition from established players in the Health Care industry.
- Economic downturns affecting healthcare spending in key markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.